Clinical Edge Journal Scan

Atopic dermatitis and immune abnormalities in children born to mothers with nickel exposure


 

Key clinical point: Maternal exposure to nickel was associated with increased serum interleukin (IL)-2 levels but decreased serum eotaxin-1 levels and was negatively associated with the development of atopic dermatitis (AD) in children aged 3 years.

Major finding: Maternal nickel exposure was associated with increased serum levels of IL-2 (β 16.820; P < .001) but decreased serum levels of eotaxin-1 (β −5.065; P < .01) and was negatively associated with the development of AD (P = .024) in children aged 3 years.

Study details: Findings are from the analysis of an ongoing birth cohort study including 140 mother-child pairs.

Disclosures: This work was supported by grants from the Ministry of Science and Technology, Taiwan, and National Health Research Institutes. The authors declared no conflicts of interest.

Source: Ho JC et al. Prenatal exposure to nickel and atopic dermatitis at age 3 years: A birth cohort study with cytokine profiles. J Eur Acad Dermatol Venereol. 2022 (Jul 16). Doi: 10.1111/jdv.18425

Recommended Reading

Vitamin D supplements during pregnancy may protect infants from atopic eczema
MDedge Dermatology
Intralesional Human Papillomavirus Vaccine Therapy for Recalcitrant Plantar Wart Triggers Gout Flare
MDedge Dermatology
Abrocitinib more promising than dupilumab in moderate-to-severe atopic dermatitis
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Long-term safety and effectiveness of tralokinumab
MDedge Dermatology
Patients with controlled atopic dermatitis can opt for dupilumab dose reduction
MDedge Dermatology
Progressive and sustained improvement in atopic dermatitis with tralokinumab plus TCS as needed
MDedge Dermatology
Dupilumab effective against pruritus in atopic dermatitis in real-life settings
MDedge Dermatology
Dupilumab effective and safe in special populations
MDedge Dermatology
Pseudoceramide+steroid cream rapidly improved skin barrier function in atopic dermatitis
MDedge Dermatology
Meta-analysis demonstrates efficacy and safety of IL-13 inhibitors in atopic dermatitis
MDedge Dermatology